"We also need to understand and remember that drugs are temporizing measures," says Wayne Kuang, MD. In this video, Wayne Kuang, MD, discusses key factors health care professionals should consider ...

Erdafitinib received full FDA approval for FGFR3-positive urothelial carcinoma, demonstrating improved overall survival in the phase 3 THOR trial. Cefepime ...

A panelist discusses how recent advances in transurethral resection of bladder tumor (TURBT) include enhanced visualization techniques like fluorescence-guided surgery and narrow-band imaging to ...

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer ...

"When I eventually met Das at an AUA annual meeting, his smile and demeanor were captivating. I had to push through the hordes of admirers to get close to him," writes Gopal H. Badlani, MD. Sakti Das, ...

"We...tried to summarize all the findings that could potentially be helpful for future research in terms of bladder cancer," says Ilaha Isali, MD, MSc. Isali ...

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer ...

TLX250-CDx aims to address unmet needs in ccRCC imaging, with a potential U.S. commercial launch in 2025. The FDA's initial concerns were related to sterility assurance, not the agent's safety or ...

“It's the sustained release and constant exposure to the gemcitabine that's most likely responsible for the high efficacy rates of that we're seeing with the TAR-200 system,” says Siamak Daneshmand, ...

"We are now in the golden era of BPH/BPO for both diagnostics and therapeutics," says Wayne Kuang, MD. In this video, Wayne Kuang, MD, shares his thoughts on what advances in benign prostatic ...

“This is another therapeutic that adds to UroGen [profile] as a potential treatment that could be used to preserve kidneys while treating low grade upper tract urothelial carcinoma going forward,” ...

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer ...